Skip to main content
NewslettersWatchlist

Kura Oncology(KURA-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low20.70
Day High21.78
Open:20.92
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
2 Incredible Growth Stocks to Buy Hand Over Fist
The Globe and Mail
U.S. equities in the spotlight for price trend enthusiasts
Barchart
Kura Oncology (KURA) Offers Speculators a Profit-Scalping Opportunity
MarketBeat
7 Best Cancer Stocks to Invest in Now
Barchart
Stock Index Futures Move Higher as Investors Await Fed Rate Decision, U.S. PPI Data
Globe Newswire
Kura Oncology Reports Second Quarter 2022 Financial Results
Globe Newswire
Kura Oncology to Participate in Wedbush PacGrow Healthcare Virtual Conference
Globe Newswire
Kura Oncology to Report Second Quarter 2022 Financial Results
Globe Newswire
Kura Oncology to Participate in Three Upcoming Investor Conferences
Globe Newswire
Kura Oncology Reports First Quarter 2022 Financial Results
Globe Newswire
Kura Oncology to Report First Quarter 2022 Financial Results
Globe Newswire
Kura Oncology Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergence of Resistance to Osimertinib in Non-Small Cell Lung Cancer
Globe Newswire
Kura Oncology Announces Multiple Abstracts Accepted for Presentation at AACR Annual Meeting
Globe Newswire
Kura Oncology to Participate in Two Upcoming Investor Conferences
Globe Newswire
Kura Oncology Reports Fourth Quarter and Full Year 2021 Financial Results
Globe Newswire
Kura Oncology to Report Fourth Quarter and Full Year 2021 Financial Results
Globe Newswire
Kura Oncology to Participate in SVB Leerink Global Healthcare Conference
Globe Newswire
Kura Oncology Expands Leadership Team with Key Promotions
Globe Newswire
Kura Oncology Receives FDA Authorization to Proceed with Phase 1b Study of KO-539 inย Acute Myeloid Leukemia
Globe Newswire
Kura Oncology Doses First Patient in Phase 1/2 Clinical Trial of Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma
Globe Newswire
Kura Oncology Reports Final Results from Phase 2 Study of Tipifarnib in T-Cell Lymphoma
Globe Newswire
Kura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Menin Inhibitor KO-539 in Combination with Venetoclax
Globe Newswire
Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute Myeloid Leukemia
Globe Newswire
Kura Oncology to Participate in Two Upcoming Investor Conferences
Globe Newswire
Kura Oncology to Participate in Credit Suisse Healthcare Conference
Globe Newswire
Kura Oncology to Report Third Quarter 2021 Financial Results
Globe NewsWire
Kura Oncology to Participate in Two Upcoming Investor Conferences
Globe NewsWire
PepGen Announces New Additions to Leadership Team and Board of Directors
Globe NewsWire
Kura Oncology Reports Second Quarter 2021ย Financial Results
Globe NewsWire
Kura Oncology to Participate in Wedbush PacGrow Healthcare Virtual Conference
Globe NewsWire
Kura Oncology to Report Second Quarter 2021 Financial Results
Globe NewsWire
Kura Oncology Appoints Helen Collins, M.D. to Board of Directors

Profile

Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright ยฉ 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright ยฉ 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.